This Week’s Biotech Highlights

This week, as Quebec moved towards paying for in vitro fertilization with the goal of reducing expensive and risky multiple births (which may or may not work), it was hard to find a singleton in the world of biotech.

Twin diagnostics projects were born this week as Warnex, the Montreal Heart Institute & CEPMED announced a project to develop a new test for cardiovascular and metabolic diseases; and CIHR and Genome Canada are funding applications of next-generation DNA sequencing technologies to combat childhood diseases.

Vancouver-based Forbes Medi-Tech found itself with twin suitors, as Pharmachem expressed interest in topping a prior bid by MHT.

Finally, the Canadian industry as a whole got a mediocre second fiscal quarter to match 2010’s first mediocre quarter, though Wayne Schnarr found some optimism in recent regulatory successes.

Stay tuned for this week’s multitude of developments at The Cross-Border Biotech Blog and @crossborderbio on Twitter.

Comments are closed.